Board of Directors

Hans is former CEO of Prosensa (acquired by BioMarin). His previous assignments include leadership roles at Genzyme and Organon. He served on the boards of Hansa Biopharma, Wilson Therapeutics (acquired by Alexion), Sobi, Asceneuron, InteRNA, Therachon (acquired by Pfizer) and VectivBio (acquired by Ironwood).

Shareholdings: View shareholding

Share awards: 31,616

Education: Pharmacist degree (PharmD) from the University of Utrecht.

Other assignments: Chairman of Microbiotica Ltd. Board member of Pharvaris NV and Organon NV. TopTeam member of the Dutch Top Sector Life Sciences & Health. Advisor to various organisations in Life Sciences & Health.

Independent of the company and its senior management and independent of major shareholders of the company.

Jacob is a former partner at HealthCap and has extensive experience in venture capital investments and investment banking related to the life sciences sector. Jacob Gunterberg has long experience as board member in both private and publicly traded companies.

Shareholdings: View shareholding

Share awards: 24,806

Education: M.Sc. in Business Administration and Economics from Lund University.

Other assignments: Board member and CFO in Purpose Pharma AB, Board member in Aurelia Invest AB, Disruptive Pharma Holding AB, EllAug AB, Tova Skrenen Stockholm AB and Twiceme Technology Sweden AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Heidi has more than 25 years of experience from leading positions in different roles within pharmaceutical development and commercialization. She has worked strategically and operationally from clinical and commercial development to launch execution. Her leadership experience spans alliance management, investment risk mitigation, global clinical and commercial management, new business strategy development, product launch, and business sustainability.

Holdings in Vicore: View shareholding

Share awards: 11,025

Education: M.B.A., Marketing and International Business, The University of Chicago. B.A., Economics and German, Magna cum laude, The University of Michigan

Other assignments: Board member Bavarian Nordic, IO Biotech and Sutro Biopharma.

Independent of the company and its senior management and independent of major shareholders of the company.

Elisabeth is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. Elisabeth Björk has been the Senior Vice President, Head of Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca leading the global development of medicines within this area since 2012. Throughout her career at AstraZeneca, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions (FDA, EMA, Japan) and commercial strategy/implementation.

Shareholdings: View shareholding

Share awards: 11,025

Education: MD, Karolinska Institute and Ph.D. in Endocrinology, Uppsala University.

Other assignments: AstraZeneca Gothenburg site lead. Board member of Calliditas Therapeutics AB, Pharvaris N.V., Agiana Pharma AS, Rocket Pharmaceuticals, Inc., Chalmers University of Technology and Betula Consulting AB.

Independent of the company and its senior management and independent of major shareholders of the company.

Michael has more than 25 years’ experience in basic research as well as from biotech and pharma R&D. Dr Buschle has held C-level positions at mid-size Pharma and biotech companies. Among others, Dr Buschle was a co-founder of vaccine company Intercell AG (merged with Vivalis to create Valneva in 2012) and President Biologics and Chief Scientific Officer at Glenmark Pharmaceuticals.

Shareholdings: View shareholding

Share awards: 11,025

Education: Ph.D. from the University of London

Other assignments: Consultant of HBM Partners AG.

Independent of the company and its senior management and independent of major shareholders of the company.

Ann has more than 20 years of drug discovery and development experience in the pharmaceutical and biotech worlds. She has contributed to several approved drugs and has worked in the rare disease, neuropsychiatry and pulmonology fields.

Share awards: –

Shareholdings: View shareholding

Education: MD, PhD.

Other assignments: Board member of Pieris Pharmaceuticals

Independent of the company and its senior management and independent of major shareholders of the company.

Yasir is a seasoned executive, board member, and strategic advisor to biotech companies. He is currently the CEO of a genetic medicines company based in California and serves as an independent board member for Maxcyte. Yasir has had operational experience running finance and business development functions at both public and private biotech companies, and prior to that had senior roles in investment banking both as an equity analyst and in corporate finance.

Share awards: –

Shareholdings: View shareholding

Education: BM BCh.

Other assignments: CEO Addition Therapeutics, Board member of Maxcyte

Independent of the company and its senior management and independent of major shareholders of the company.